125 related articles for article (PubMed ID: 24628295)
1. Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back.
Alwan AF; Matti BF; Naji AS; Muhammed AH; Abdulsahib MA
Leuk Lymphoma; 2014 Dec; 55(12):2830-4. PubMed ID: 24628295
[TBL] [Abstract][Full Text] [Related]
2. Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety.
Saavedra D; Vizcarra F
Leuk Lymphoma; 2014 Dec; 55(12):2813-6. PubMed ID: 24724785
[TBL] [Abstract][Full Text] [Related]
3. High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.
Petzer AL; Fong D; Lion T; Dyagil I; Masliak Z; Bogdanovic A; Griskevicius L; Lejniece S; Goranov S; Gercheva L; Stojanovic A; Peytchev D; Tzvetkov N; Griniute R; Stanchev A; Grubinger T; Kwakkelstein M; Schuld P; Gastl G; Wolf D
Haematologica; 2012 Oct; 97(10):1562-9. PubMed ID: 22511495
[TBL] [Abstract][Full Text] [Related]
4. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.
Latagliata R; Ferrero D; Iurlo A; Cavazzini F; Castagnetti F; Abruzzese E; Fava C; Breccia M; Annunziata M; Stagno F; Tiribelli M; Binotto G; Mansueto G; Gozzini A; Russo S; Cavalli L; Montefusco E; Gugliotta G; Cedrone M; Russo Rossi A; Avanzini P; Pregno P; Mauro E; Spadea A; Celesti F; Giglio G; Isidori A; Crugnola M; Calistri E; Sorà F; Storti S; D'Addosio A; Rege-Cambrin G; Luciano L; Alimena G
Drugs Aging; 2013 Aug; 30(8):629-37. PubMed ID: 23681399
[TBL] [Abstract][Full Text] [Related]
5. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
Cervantes F; López-Garrido P; Montero MI; Jonte F; Martínez J; Hernández-Boluda JC; Calbacho M; Sureda A; Pérez-Rus G; Nieto JB; Pérez-López C; Román-Gómez J; González M; Pereira A; Colomer D
Haematologica; 2010 Aug; 95(8):1317-24. PubMed ID: 20220063
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
Hughes TP; Hochhaus A; Kantarjian HM; Cervantes F; Guilhot F; Niederwieser D; le Coutre PD; Rosti G; Ossenkoppele G; Lobo C; Shibayama H; Fan X; Menssen HD; Kemp C; Larson RA; Saglio G
Haematologica; 2014 Jul; 99(7):1204-11. PubMed ID: 24532039
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.
Gallipoli P; Stobo J; Heaney N; Nicolini FE; Clark R; Wilson G; Tighe J; McLintock L; Hughes T; Michor F; Paul J; Drummond M; Holyoake TL
Br J Haematol; 2013 Dec; 163(5):674-6. PubMed ID: 24032404
[No Abstract] [Full Text] [Related]
8. Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients.
Scalzulli E; Colafigli G; Latagliata R; Pepe S; Diverio D; Stocchi F; Di Prima A; Efficace F; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Dec; 99(12):2773-2777. PubMed ID: 32462330
[TBL] [Abstract][Full Text] [Related]
9. Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil.
Silveira CA; Daldegan MB; Ferrari I
Genet Mol Res; 2011 Sep; 10(3):2038-48. PubMed ID: 21968620
[TBL] [Abstract][Full Text] [Related]
10. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137
[TBL] [Abstract][Full Text] [Related]
11. Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase.
Mattar M
Int J Hematol; 2010 Jan; 91(1):104-6. PubMed ID: 20054670
[TBL] [Abstract][Full Text] [Related]
12. High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis.
Gafter-Gvili A; Leader A; Gurion R; Vidal L; Ram R; Shacham-Abulafia A; Ben-Bassat I; Lishner M; Shpilberg O; Raanani P
Am J Hematol; 2011 Aug; 86(8):657-62. PubMed ID: 21761431
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
Breccia M; Cannella L; Stefanizzi C; Latagliata R; Nanni M; Diverio D; Santopietro M; Federico V; Alimena G
Hematol Oncol; 2010 Jun; 28(2):89-92. PubMed ID: 19728398
[TBL] [Abstract][Full Text] [Related]
14. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
[TBL] [Abstract][Full Text] [Related]
15. [A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up].
Hołowiecki J; Konopka L; Bober G; Giebel S; Ceglarek B; Kos K; Stella-Hołowiecka B; Kruzel T; Kopera M; Bartkowska-Chrobok A; Pszenna E; Sikorska A; Pieńikowska-Grela B
Pol Arch Med Wewn; 2006 Jun; 115(6):535-44. PubMed ID: 17263225
[TBL] [Abstract][Full Text] [Related]
16. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.
Santos FP; Alvarado Y; Kantarjian H; Verma D; O'Brien S; Mattiuzzi G; Ravandi F; Borthakur G; Cortes J
Cancer; 2011 Mar; 117(5):982-91. PubMed ID: 20960502
[TBL] [Abstract][Full Text] [Related]
17. Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib.
La Rosée P; Martiat P; Leitner A; Klag T; Müller MC; Erben P; Schenk T; Saussele S; Hochhaus A
Ann Hematol; 2013 Oct; 92(10):1345-50. PubMed ID: 23625298
[TBL] [Abstract][Full Text] [Related]
18. Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia.
Ross DM; Jackson SR; Browett PJ
Leuk Lymphoma; 2007 Jun; 48(6):1231-3. PubMed ID: 17577792
[No Abstract] [Full Text] [Related]
19. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
Cortes JE; Baccarani M; Guilhot F; Druker BJ; Branford S; Kim DW; Pane F; Pasquini R; Goldberg SL; Kalaycio M; Moiraghi B; Rowe JM; Tothova E; De Souza C; Rudoltz M; Yu R; Krahnke T; Kantarjian HM; Radich JP; Hughes TP
J Clin Oncol; 2010 Jan; 28(3):424-30. PubMed ID: 20008622
[TBL] [Abstract][Full Text] [Related]
20. Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients.
Breccia M; Latagliata R; Molica M; Colafigli G; Mancini M; Diverio D; Tafuri A; Alimena G
Am J Hematol; 2015 May; 90(5):E95-6. PubMed ID: 25683237
[No Abstract] [Full Text] [Related]
[Next] [New Search]